Oct 2, 2026 08:00AM
May 18, 2026 08:00AM
May 14, 2026 10:55AM
May 12, 2026 09:04AM
May 12, 2026 09:00AM
Apr 30, 2026 09:00AM
Apr 20, 2026 06:45AM FDA grants priority review to Astellas-Pfizer cancer drug application
Apr 20, 2026 06:45AM
Feb 27, 2026 10:04AM
Feb 27, 2026 10:00AM
Jan 8, 2026 10:30AM
Dec 17, 2025 06:45AM
Dec 10, 2025 06:30PM
Dec 5, 2025 08:00AM Astellas To Present New Data on XOSPATA™ (gilteritinib) Across the FLT3m+ AML Disease Continuum at ASH 2025 Annual Meeting
Nov 21, 2025 01:24PM
Nov 21, 2025 01:24PM
Oct 23, 2025 08:00AM
Oct 22, 2025 08:00AM
Oct 21, 2025 07:30PM
Oct 21, 2025 07:30PM
Oct 19, 2025 07:30PM IZERVAY™ (avacincaptad pegol intravitreal solution) Showed Increased Benefit in Reducing Geographic Atrophy Progression Over Time and Consistent Long-Term Safety
Oct 14, 2025 08:00PM
Oct 8, 2025 07:30PM
May 1, 2025 09:00AM
Feb 12, 2025 06:32PM
Jan 8, 2025 06:30PM
Dec 5, 2024 08:49AM
Nov 20, 2024 01:00PM Astellas Announces Desert Oasis Healthcare as First Health System to Implement DIGITIVA™ for Heart Failure Management
Oct 18, 2024 02:13PM
Oct 10, 2024 01:00PM
Sep 24, 2024 02:05AM
Sep 18, 2024 07:30PM
Sep 4, 2024 08:00AM
Aug 27, 2024 07:30PM
Jul 26, 2024 11:39AM Astellas Receives Positive CHMP Opinion for PADCEV™ (enfortumab vedotin) in combination with KEYTRUDA® (pembrolizumab) for First-Line Treatment of Advanced Bladder Cancer
May 30, 2024 10:30PM
Apr 23, 2024 07:30PM
Mar 28, 2024 11:00AM
Mar 26, 2024 08:30AM
Mar 22, 2024 08:00AM
Mar 11, 2024 09:00AM
Feb 15, 2024 06:30PM PADCEV™ (enfortumab vedotin (genetical recombination)) with KEYTRUDA® (pembrolizumab (genetical recombination)) Granted Priority Review by Japan's Ministry of Health, Labour and Welfare for First-L
Feb 1, 2024 07:00AM
Jan 30, 2024 09:00PM
Jan 26, 2024 12:01PM
Jan 26, 2024 12:00PM
Jan 26, 2024 12:00PM
Jan 8, 2024 06:30PM
Dec 8, 2023 01:18PM FDA Approves Expanded Use of CRESEMBA® (isavuconazonium sulfate) in Children with Invasive Aspergillosis and Invasive Mucormycosis
Nov 16, 2023 10:33PM

334,868 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All